Uritos is a selective M3 receptor antagonist primarily used to treat urinary frequency, urgency, and urge incontinence caused by overactive bladder (OAB). When administering the medication, it is important to pay attention to anticholinergic side effects, prohibited populations, and dosage adjustments for special patients.

1. Indications

(1) Overactive bladder: Applicable to adult patients with overactive bladder characterized by urinary urgency, urinary frequency, and/or urge urinary incontinence.

(2) Other indications: Approved in some countries for adjuvant therapy of neurogenic bladder dysfunction, but local instructions must be strictly followed.

2. Medication precautions

(1) Contraindications: This product is contraindicated for patients with glaucoma, severe ulcerative colitis, myasthenia gravis, and those who are allergic to it.

(2) Anticholinergic side effects: These may include dry mouth, constipation, blurred vision, etc. Elderly patients are more prone to these effects, which require close monitoring.

(3) Cardiovascular risk: Use with caution in patients with QT interval prolongation, and avoid combination with other QT interval prolonging drugs.

(4) Hepatic and renal insufficiency: Dose reduction is required for patients with moderate hepatic impairment, and use is not recommended for patients with severe hepatic and renal insufficiency.

(5) Special population: Safety during pregnancy has not been established, and breastfeeding should be suspended during lactation; there is insufficient safety data for pediatric use.

3. Dosage and Administration

(1) Conventional dosage: The recommended dosage for adults is 0.1mg per dose, taken twice daily after meals to reduce gastrointestinal discomfort.

(2) Dose adjustment: Based on efficacy and tolerability, the dosage can be gradually increased to a maximum of 0.2 mg per dose, administered twice daily under the guidance of a doctor.

(3) Handling of missed doses: If a dose is missed, it should be taken as soon as possible. If it is close to the next scheduled dose, skip it and do not take a double dose.

4. Drug interactions

(1) CYP3A4 inhibitors: Drugs like ketoconazole may increase the plasma concentration of imatinib, necessitating cautious combination use and consideration of dose reduction.

(2) Cholinergic drugs: May antagonize the efficacy of cholinergic drugs, requiring attention to adjusting the dosage or dosing interval.

(3) Other anticholinergic drugs: Concurrent use may enhance anticholinergic side effects, and simultaneous use should be avoided.